India's pharmaceutical exports showed steady progress, reaching $28.29 billion through February of the 2026 financial year. This figure represents a 5.6% year-on-year increase, with key drivers including formulations, biologics, and vaccines. While this growth continues, it is slower than the 9.4% increase seen in the previous financial year (FY24-25), which ended with total shipments of $30.47 billion. The Indian pharmaceutical sector, currently valued around $60 billion, is still expected to grow significantly, with projections to exceed $130 billion by 2030.
Growth Slows Amid Market Shifts
The Indian pharmaceutical sector is navigating a more complex global landscape. The Nifty Pharma Index has shown mixed results, trading nearly flat year-to-date by late March 2026, compared to a more than 10% drop in the broader Nifty 50 index. Pharma's relative stability highlights its defensive appeal, but growth factors face pressure. For example, while the sector saw 12.3% growth in the December 2025 quarter, this was boosted by domestic sales and European markets. US revenue growth remained slow, partly due to lower sales of certain drugs. Global pharmaceutical production, which surged in 2025, is now expected to grow more slowly at 1.6% in 2026.
Innovation and Scrutiny Drive Changes
India's drug industry is shifting focus from high-volume generics to innovation, emphasizing complex generics, biosimilars, and specialty products. This change is vital as key markets like the US increase pricing pressure and regulatory oversight. USFDA inspections show improved compliance for Indian plants, with 'Official Action Indicated' (OAI) findings dropping to 8% in 2025 from 12% in 2015. This is a positive sign compared to global trends. However, issues like data integrity problems and specific plant actions, such as Sun Pharma's Halol facility receiving an OAI classification in June 2025, still show ongoing risks. New US trade measures, including a recent tariff on patented drug imports (generics currently exempt), also create uncertainty and encourage bringing supply chains closer to home.
Geopolitical conflicts, especially in West Asia, are affecting major shipping routes. This has caused higher freight costs and potential delays, particularly for shipments requiring special temperature controls. These disruptions may have cost Indian exporters between ₹2,500-₹5,000 crore in March alone for shipments to the Gulf Cooperation Council (GCC) and surrounding regions. The industry also faces challenges in research and development (R&D) investment. Indian companies typically invest 7-8% of revenue, lower than global competitors, which could affect the development of new medicines.
Rising Risks for the Sector
Although export numbers show steady progress, deeper analysis reveals growing challenges that could slow future growth. A tougher regulatory environment, with stricter oversight from the USFDA and EU, requires constant investment in quality and compliance systems. This burden particularly affects smaller companies. Relying heavily on the large US market also exposes the sector to significant pricing pressures, especially in generics where competition is strong and profits are shrinking. Potential trade protectionism, tariffs, and supply chain disruptions add considerable business risks. Stock valuations for major Indian pharma companies, such as Sun Pharma (P/E ~37), Dr. Reddy's Laboratories (P/E ~18), Cipla (P/E ~21), and Lupin (P/E ~22.5), reflect how investors view their ability to handle these issues. Dr. Reddy's Laboratories, for instance, seems fairly valued given its broad strategy, while Sun Pharma's higher valuation suggests strong investor confidence in its size and specialized products.
Future Outlook
Analysts forecast India's pharmaceutical sector to grow by 9-11% in FY2026, supported by domestic growth and strategic expansion in markets like Europe. Key priorities for the industry include quality improvements, sustainable practices, and diversifying markets to reduce reliance on any one region. The move towards innovation and higher-value products should improve long-term strength. However, continued success will depend on the industry's ability to adapt to changing regulations, manage supply chain weaknesses, and invest in R&D for new discoveries, going beyond just improving current processes.